Get the Stockscreener App
36.78
0.74%
0.27
Cue Biopharma Inc stock is traded at $36.78, with a volume of 287.58K.
It is up +0.74% in the last 24 hours and up +32.02% over the past month.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
See More
Previous Close:
$36.51
Open:
$40.57
24h Volume:
287.58K
Relative Volume:
0.41
Market Cap:
$154.49M
Revenue:
$32.73M
Net Income/Loss:
$-19.52M
P/E Ratio:
-6.654
EPS:
-5.5275
Net Cash Flow:
$-24.61M
1W Performance:
+30.15%
1M Performance:
+32.02%
6M Performance:
+240.08%
1Y Performance:
+54.02%
1-Day Range:
$36.77
$45.50
1-Week Range:
$28.01
$45.50
52-Week Range:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
36.78 | 154.49M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Form 4 Cue Biopharma For: 10 July By Investing.com - Investing.com Canada
Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone - Stock Titan
Cue Biopharma (CUE) awards 21,800 restricted stock units to board director - Stock Titan
Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award - Stock Titan
Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant - Stock Titan
Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief - Stock Titan
Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief - Stock Titan
Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package - Stock Titan
Cue Biopharma Announces $50 Million Private Placement - TipRanks
Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle - TradingView
Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs - Stock Titan
Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE) - Seeking Alpha
Cue Biopharma Shares Rise on $50 Million Private Placement Pricing - Moomoo
CUE: Cue Biopharma Secures $50M in Private Placement - GuruFocus
Cue Biopharma (CUE) Secures $50M in Private Placement Financing - GuruFocus
Cue Biopharma to raise $50M in oversubscribed private placement - MSN
CUE BIOPHARMA ANNOUNCES $50.0 MILLION PRIVATE PLACEMENT - Moomoo
Cue Biopharma raises $50M in private placement By Investing.com - Investing.com South Africa
Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs - Stock Titan
Cue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset Management - Quiver Quantitative
Cue Biopharma Announces $50.0 Million Private Placement - GlobeNewswire Inc.
Cue Biopharma Company Profile & Introduction - Moomoo
Cue Biopharma Inc outlines its immunotherapy approach for long-term investors - ad-hoc-news.de
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Signal Law Group Issues VRS Bulletin on Cue Biopharma, Inc. (CUE) - The Daily Tribune News
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Growth Benchmark - marketscreener.com
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell 3000E Index - marketscreener.com
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Index - marketscreener.com
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc.(NasdaqCM: CUE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Price to book forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Cue Biopharma(CUE) Stock Options Chain | Quotes & News - Moomoo
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to sales forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Enterprise value to revenue forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to earnings forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Price to sales forward of Cue Biopharma, Inc. – LS:A426PN - TradingView
Long term debt to total equity ratio of Cue Biopharma, Inc. – LS:A426PN - TradingView
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lin Shao-Lee - Moomoo
Cue Biopharma Stocklong-term strategy in immuno-oncology - AD HOC NEWS
Cue Biopharma Inc (CUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
CUE BIOPHARMA INC (CUE) Stock Chart - ChartMill
Cue Biopharma (NASDAQ: CUE) registers 551,724 pre-funded-warrant shares for resale - Stock Titan
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cue Biopharma | EFFECT: Others - Moomoo
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Inc (CUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):